참고문헌
- A. Fleckenstein, Specific pharmacology of calcium in myo-cardium. cardiac pacemakers, and vascular smooth muscle. Annual Review of Pharmacology and Toxicology, 17, 149-166 (1977) https://doi.org/10.1146/annurev.pa.17.040177.001053
- D.M. Krikler and RAl Spurrel, verapamil in the treatment of paroxysmal supraventricular tachycardias. Postgraduate Medicine., 50, 447-453 (1974) https://doi.org/10.1136/pgmj.50.585.447
- B.A Gould, S. Mann, H. Kieso, Y. Bala Subramanian and E.B. Raftery, The 24-hour ambulatory blood pressure profile with verapamiI. Circulation., 65, 22-27 (1982) https://doi.org/10.1161/01.CIR.65.1.22
- G.R.J. Lewis, KD. Morley, B.M. Lewis and P.l Bones, The treatment of hypertension with verapamil. N.Z. Medical Journal, 87, 351-354 (1978)
- M. Schomerus, B. Spiegelhaider, B. Stieren and M. Eichelbaum, Physiologic disposition of verapamil in man. Cardiovascular Research, 10, 605-612 (1976) https://doi.org/10.1093/cvr/10.5.605
- G. Neugebauer, Comparative cardiovascular actions of verapamil and its major metabolites in the anesthetized dog. Cardiovascular Research, 12, 247-254 (1978) https://doi.org/10.1093/cvr/12.4.247
-
M. Eichelbaum. E.G. Remberg, M. Schomerus and H.J. Dengler, The metabolism of
$D,L(^{14}C)$ verapamil in man. Drug Metabolism and Disposition, 7, 145-148 (1979) -
M. Eichelbaum, G. Mikus and B. Vogelgesang, Pharmacokinetics of (+)-, (-)- and
$(\pm)-verapamil$ after intravenous administration. British Journal of Clinical Pharmacology, 17, 453-458 (1984) https://doi.org/10.1111/j.1365-2125.1984.tb02371.x - B.G. Woodcock, I. Rietbrock, H. Voehringer and N. Rietbrock, veraparnil disposition in liver disease and intensivecase patients: kinetics, clearance, and apparent blood flow relationships. Clinical Pharmacology and Therapeutics. 29, 27-34 (1981) https://doi.org/10.1038/clpt.1981.5
- M. Eichelbaum, M. Albrecht, K Kliems, K Schafe and A Somogyi, Influence of mesocaval shunt surgery on verapamil kinetics, bioavailability and response. British Journal of Clinical Pharmacology, 10, 527-529 (1980) https://doi.org/10.1111/j.1365-2125.1980.tb01800.x
- J.B. Schwartz, D.R Abernethy, A.A Taylor and J.R Mitchel, An investigation of the cause of accumulation of veraparnil during regular dosing in patients. British J. Clinical Pharmacology, 19, 512-516 (1985) https://doi.org/10.1111/j.1365-2125.1985.tb02678.x
- S.B. Freedman, DR Richmond, J.J. AsWey and D.T. Kelly, veraparni1 kinetics in normal subjects and patients with coronary artery spasm. Clinical Pharmacology and Thera-peutics, 30, 644-652 (1981) https://doi.org/10.1038/clpt.1981.216
- M. Eichelbaum, P. Birkel, E. Grube, U. Gutgemann and A Somogyi, Effects of veraparnil on PR intervals in relation to veraparnil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift. 58, 919-925 (1980) https://doi.org/10.1007/BF01477049
- G. Mikus, Die Anwendung eines mit stabilen isotopen markierten Arzneimittels zur sirnultanen Bestimmung der relativen biologischem Verfugbarkeit einer verapamil retard Thesis, University of Bonn. (1985)
- J.A Dominic, D.w.A. Bourne, T.G. Tan, E.B. Kirsten and R.G. McAllister, The pharmacology of verapamil. III. Pharmaco-kinetics in normal subjects after intravenous drug admini-stration. J. Cardiovascular Pharmacology, 3, 25-38 (1981) https://doi.org/10.1097/00005344-198101000-00003
- R.G. McAllister, Clinical pharmacology of slow channel blocking agents. Progress in Cardiovascular Diseases, 25, 83102 (1982) https://doi.org/10.1016/0033-0620(82)90022-6
- F.X. McGowan, MJ. Reiter, ELe. Pritchett and D.G. Shand, veraparnil plasma binding: Relationship to alphajacid glycoprotein and drug efficacy. Clinical Pharmacology and Therapeutics, 33, 485-490 (1983) https://doi.org/10.1038/clpt.1983.66
- D.L. Keefe, YG. Yee and RE. Kates, veraparnil protein binding in patients and in normal subjects. Clin. Pharm. and Therapeutics, 29, 21-26 (1981) https://doi.org/10.1038/clpt.1981.4
- C.M. Loi, D.E. Rollins, G.E. Dukes and Peat, M. A Effect of cirnetidine on veraparnil disposition. Clin. Pharm. and Therapeutics, 37, 654-657 (1985) https://doi.org/10.1038/clpt.1985.106
- L.M. Johnson, S.M. Lankford and SA Bai, The influence of cirnetidine on the pharmacokinetics of the enantiomers of veraparnil in the dog during multiple oral dosing. J. Vet. Pharmacol. Ther., 18, 117-123 (1995) https://doi.org/10.1111/j.1365-2885.1995.tb00564.x
- L.M.H. Wing, J.O. Miners and K.I. Lillywhite, veraparnil disposition effects of sulphinpyrazone and cirnetidine. British Journal of Clinical Pharmacology, 19, 385-391 (1985) https://doi.org/10.1111/j.1365-2125.1985.tb02658.x
- D.R. Abernethy, lB. Schwatz and E.L. Todd, Lack of interaction between verapamil and cirnetidine. Clinical Pharmacology and Therapeutics, 38, 342-349 (1985) https://doi.org/10.1038/clpt.1985.183
- P.C. Ho, K. Ghose, D. Saville and S. Wanwirnolruk, Effect of grapefruit juice on the pharmacokinetics and pharmacody-namics of veraparnil enantiomers in healthy volunteers. Eur. J. Clin. Pharmacol, 56, 693-698 (2000) https://doi.org/10.1007/s002280000189
- U. Fuhr, H. Muller-Peltzer, R Kern and S. Harder, Effect of grapefruit juice and smoking on veraparnil concentration steady state. Eur. J. Clin. Pharmacol, 58, 45-53 (2002) https://doi.org/10.1007/s00228-002-0436-7
- R Zaidenstein, Y. Dishi, M. Gips, S. Soback, N. Cohen, J. Weissgarten, A Blatt and A Golik, The effect of grapefruit juice on the pharmacokinetics of orally administered veraparniI. Eur. J. Clin. Pharmacol, 54, 337-340 (1988) https://doi.org/10.1007/s002280050470
- E. Verzino, B. Kaplan, J.Y. AsWey and M. Burdette, verapamil aspirin interaction. Ann. Pharmacother, 28, 536-7 (1994)
- D. Orszulak-Michalak, AK Wiktorowska-Owczarek and J. Owczarek, Influence of midazolam on pharmacokinetics of veraparni1 in rabbits. Poz. 1. Pharmacol, 54, 501-506 (2002)
- R.A Lugo. and M.e. Nahata, veraparnil interaction with ceftriaxone and clindamycin. Ann. Pharmacother, 27, 877-80 (1993) https://doi.org/10.1177/106002809302700711
- R. Sandstrom, A Karlsson, L. Knutson and H. Lennernas, Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res., 15, 856-862 (l998) https://doi.org/10.1023/A:1011916329863
- Y.J. Wacher, C.Y. Wu and L.Z. Benet, Overlapping substrate specificities and tissue distribution of cytochrome p450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13, 129-134 (1995) https://doi.org/10.1002/mc.2940130302
- V. Cody, Plant flavoniods in biology and medicine. Prog. Clin. BioI. Res., 213, 233-239 (1986)
- V. Cody, Plant flavonoids in biology and medicine, part . Prog Clin. BioI. Res., 280, 111-120 (1988)
- P.C.H. Hollman, M.V.D. Gaag and M.V.D. Mengelers, Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr., 62, 1276-1282 (1995) https://doi.org/10.1093/ajcn/62.6.1276
- U. Takahama, Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry, 24, 1443-1446 (1985) https://doi.org/10.1016/S0031-9422(00)81040-7
- E.N. Frankel, J.B. German, E. Parks and J.E. Kinsella, Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wind. The Lancet., 341, 454-457 (1993) https://doi.org/10.1016/0140-6736(93)90206-V
- M.T. Murray, Quercetin: Nature's antihistamine. Better Nutrition, 60, 10-16 (1998)
- W. Davis, M.S. Lamson, S. Matthew and N.D. Brignall, Antioxidants cancer : Quercetin. Alternative Medicine Review, 5, 196-208 (2000)
- D.R. Ferry, A. Smith, J. Malkhandi, DW. Fyfe, P.G. deTakats, D. Anderson, J. Baker and DR Kerr, Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Research, 2, 659-668 (1996)
- J. Terao, M. Piskula, C. Rice-Evans and L. Packer, Flavonoids in health and disease, Marcel Dekker, New York: pp. 277-293 (1998)
- G. Soambia, EO. Ranellett, Panici, P.E. D.R. Vincenzo, G. Bonanno, G. Frrandina, M. Piantelli, S. Bussa, C. Rurni and M. Ciantriglia, Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacal, 36, 448-450 (1995)
- C.H. Choi, N. Romiti, E Cervelli and R. Tongiani, Effect of flavonols on P-glycoprotein activety in cultured rat hepatocytes. Life Sciences, 57, 1741-1750 (1995) https://doi.org/10.1016/0024-3205(95)02152-9
- H. Zhang, C.W Wong, P.G. Coville and S. Wanwimolruk, Effect of the grapefruit flavonoid naringen on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact, 17, 351-363 (2000)
- G.N. Kumar, UK Walle and T. Walle, Cytochrome P450 3Amediated human liver microsomal taxol to 6 alphahydroxylation. J. Pharmacal. Exp. Ther., 268, 1160-1165 (1994)
- A. Rahman, KR Korzekwa, J. Grogan, F.J. Gonzalez and J.W Harris, Selective biotransformation of taxol to 6 alphahydroxytaxo1 by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994)
- 식품의약품안전청, 국립독성연구소, 생물학적동등성시험 펴시준지침, 식품의약품안전청, pp. 142-146 (2003)
- M.L. Rocci and W.j. Jusko, LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine, 16, 203-209 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
- J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein mediated multidrug resistance. Ann. Rev. Biochem., 58, 137-171 (1989) https://doi.org/10.1146/annurev.bi.58.070189.001033
- J.S. Choi, HK Choi and S.c. Shin, Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. European Journal of Phannaceutics and Biopharmaceutics. in press (2004)
- S.L. Hsiu, Y.C. Hou, Y.H. Wang, C.W. Tsao, S.E Su and P.D. Chao, Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci., 72, 227-235 (2002) https://doi.org/10.1016/S0024-3205(02)02235-X